Merck + Co., Inc.

Brian T Phillips

George D Hartman

Wayne J Thompson

Peter M Munson

David A Claremon

Nigel J Liverton

John A McCauley

John W Butcher

Wasyl Halczenko

Christopher F Claiborne

Brian E Libby

Kevin T Nguyen

John J Baldwin

Joseph P Vacca

Mark E Fraley

Gerald S Ponticello

Craig Alan Coburn

Steven D Young

Mark E Layton

Philip E Sanderson

Randall W Hungate

Charles J McIntyre

Adel M Naylor-Olsen

S Dale Lewis

Christine Dieckhaus

Willie Whitter

Compounds represented by Formula (I) or pharmaceutically acceptable salts thereof, are effective as NMDA/NR2B antagonists useful for treating neurological conditions such as, for example, pain, Parkinson's disease, Alzheimer's disease, epilepsy, depression, anxiety, ischemic brain injury including stroke, and other conditions. 

4-cycloakylaminopyrazolo pyrimidine NMDA/NR2B antagonists

Compounds represented by Formula (I): (I) or pharmaceutically acceptable salts thereof, are effective as NMDA NR2B antagonists useful for relieving pain 

N-substituted nonaryl-heterocyclic NMDA/NR2B antagonists

Compounds represented by Formula (I): or pharmaceutically acceptable salts thereof, are effective as NMDA NR2B antagonists useful for relieving pain.

Novel 3-substituted 8-aza-bicyclo&lsqb;3.2.1&rsqb;octanes (commonly known as &ldquo;tropanes&rdquo;) substituted in the 8-position are effective as NMDA NR2B antagonists useful for relieving pain.

8-aza-bicyclo&lsqb;3.2.1&rsqb;octane NMDA/NR2B antagonists

A compound which inhibits human thrombin and which has the general structure ##STR1##

Thrombin inhibitors

Novel fused polycyclic and bridged compounds are disclosed which are useful as calcium entry blockers.

Fused polycyclic and bridged compounds useful as calcium channel blockers

Novel substituted 4-heteroaryl-1,4-dihydropyridine compounds useful as calcium channel blockers, pharmaceutical compositions therof, and methods of treatment are disclosed.

Certain 1,4-dihydro-2,6-di-lower hydrocarbyl-4-heterocyclic-3,5-pyridine

Novel N-substituted tetrahydropyridine compounds are disclosed. The compounds have the property of inhibiting calcium induced contraction of smooth muscle and are adaptable to being employed in the chemotherapeutic treatment of cardiovascular diseases.

Cyclized N-substituted-tetrahydropyridine compounds and cardiovascular

Benzo(f)isoquinoline compounds, particularly, penta- and tetrahydrobenzo(f)isoquinoline dicarboxylic acid compounds, their preparation and their use as calcium entry blockers are disclosed.

Benzo(f)isoquinoline compounds useful as calcium entry blockers

Novel substituted and bridged pyridine compounds useful as calcium channel blockers, pharmaceutical compositions thereof, and methods of treatment are disclosed.

Growing community of inventors

Telford, PA, United States of America

Brian T Phillips